• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胰腺癌胰腺切除术后延长的术后血栓预防与微创入路中静脉血栓栓塞风险降低相关。

Extended postoperative thromboprophylaxis after pancreatic resection for pancreatic cancer is associated with decreased risk of venous thromboembolism in the minimally invasive approach.

作者信息

Sood Divya, Kuchta Kristine, Paterakos Pierce, Schwarz Jason L, Rojas Aram, Choi Sung H, Vining Charles C, Talamonti Mark S, Hogg Melissa E

机构信息

Department of Surgery, University of Chicago, Chicago, Illinois, USA.

Department of Surgery, NorthShore University HealthSystem, Evanston, Illinois, USA.

出版信息

J Surg Oncol. 2023 Mar;127(3):413-425. doi: 10.1002/jso.27135. Epub 2022 Nov 11.

DOI:10.1002/jso.27135
PMID:36367398
Abstract

BACKGROUND

Pancreatic ductal adenocarcinoma (PDAC) is associated with increased venous thromboembolism (VTE). We sought to compare rates of bleeding complications and VTE in patients receiving extended postoperative thromboprophylaxis (EPT) to those who did not, and identify risk factors for VTE after pancreatectomy for PDAC.

METHODS

This is a retrospective review of pancreatectomies for PDAC. EPT was defined as 28 days of low molecular weight heparin. Multivariable analysis (MVA) was performed to identify independent risk factors of VTE.

RESULTS

Of 269 patients included, 142 (52.8%) received EPT. Of those who received EPT, 7 (4.9%) suffered bleeding complications, compared to 6 (4.7%) of those who did not (p = 0.938). There was no significant difference in VTE rate at 90 days (2.8% vs. 2.4%, p = 0.728) or at 1 year (6.3% vs. 7.9%, p = 0.624). On MVA, risk factors for VTE included worse performance status, lower preoperative hematocrit, R1/R2 resection, and minimally invasive (MIS) approach. Among those who received EPT, there was no difference in VTE rate between MIS and open approach.

CONCLUSIONS

EPT was not associated with a difference in VTE risk or bleeding complications. MIS approach was associated with a higher risk of VTE; however, this was significantly lower among those who received EPT.

摘要

背景

胰腺导管腺癌(PDAC)与静脉血栓栓塞(VTE)风险增加相关。我们旨在比较接受延长术后血栓预防(EPT)的患者与未接受该预防措施的患者的出血并发症和VTE发生率,并确定PDAC胰腺切除术后VTE的危险因素。

方法

这是一项对PDAC胰腺切除术的回顾性研究。EPT定义为使用低分子量肝素28天。进行多变量分析(MVA)以确定VTE的独立危险因素。

结果

纳入的269例患者中,142例(52.8%)接受了EPT。接受EPT的患者中,7例(4.9%)出现出血并发症,未接受EPT的患者中有6例(4.7%)出现出血并发症(p = 0.938)。90天时VTE发生率(2.8%对2.4%,p = 0.728)或1年时(6.3%对7.9%,p = 0.624)无显著差异。在MVA中,VTE的危险因素包括较差的体能状态、较低的术前血细胞比容、R1/R2切除以及微创(MIS)手术方式。在接受EPT的患者中,MIS手术方式和开放手术方式的VTE发生率无差异。

结论

EPT与VTE风险或出血并发症的差异无关。MIS手术方式与较高的VTE风险相关;然而,在接受EPT的患者中,这种风险显著降低。

相似文献

1
Extended postoperative thromboprophylaxis after pancreatic resection for pancreatic cancer is associated with decreased risk of venous thromboembolism in the minimally invasive approach.胰腺癌胰腺切除术后延长的术后血栓预防与微创入路中静脉血栓栓塞风险降低相关。
J Surg Oncol. 2023 Mar;127(3):413-425. doi: 10.1002/jso.27135. Epub 2022 Nov 11.
2
Risk of Venous Thromboembolism for Patients with Pancreatic Ductal Adenocarcinoma Undergoing Preoperative Chemotherapy Followed by Surgical Resection.接受新辅助化疗后手术切除的胰腺导管腺癌患者的静脉血栓栓塞风险。
Ann Surg Oncol. 2019 May;26(5):1503-1511. doi: 10.1245/s10434-018-07148-z. Epub 2019 Jan 16.
3
Neoadjuvant Chemotherapy is Associated with Increased Risk of Postoperative DVT After Distal Pancreatectomy for Pancreatic Adenocarcinoma: a NSQIP Analysis.新辅助化疗与胰腺腺癌胰体尾切除术后术后深静脉血栓形成风险增加相关:一项 NSQIP 分析。
Ann Surg Oncol. 2024 May;31(5):2873-2881. doi: 10.1245/s10434-023-14763-y. Epub 2023 Dec 27.
4
Timing of preoperative pharmacoprophylaxis for pancreatic surgery patients: a venous thromboembolism reduction initiative.术前预防性给药时机对胰腺手术患者的影响:一项静脉血栓栓塞症防治计划。
Ann Surg Oncol. 2012 Jan;19(1):19-25. doi: 10.1245/s10434-011-1858-1. Epub 2011 Jul 2.
5
Extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: A systematic review and meta-analysis of the literature.大腹部/骨盆癌症相关手术后的延长血栓预防:文献的系统评价和荟萃分析。
Thromb Res. 2021 Aug;204:114-122. doi: 10.1016/j.thromres.2021.06.010. Epub 2021 Jun 19.
6
Venous Thromboembolism Incidence and Prophylaxis Use After Gastrectomy Among Korean Patients With Gastric Adenocarcinoma: The PROTECTOR Randomized Clinical Trial.胃腺癌韩国患者胃切除术后静脉血栓栓塞发生率和预防应用:PROTECTOR 随机临床试验。
JAMA Surg. 2018 Oct 1;153(10):939-946. doi: 10.1001/jamasurg.2018.2081.
7
Predictive accuracy of boosted regression model in estimating risk of venous thromboembolism following minimally invasive radical surgery in pharmacological prophylaxis-naïve men with prostate cancer.在药物预防-naive 的前列腺癌男性中,预测最小侵入性根治手术后静脉血栓栓塞风险的增强回归模型的预测准确性。
World J Surg Oncol. 2024 Feb 23;22(1):67. doi: 10.1186/s12957-023-03170-y.
8
Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.高危外科和内科患者出院后使用低分子量肝素进行延长血栓预防:一项综述
Clin Ther. 2009 Jun;31(6):1129-41. doi: 10.1016/j.clinthera.2009.06.002.
9
Prevention of Venous Thromboembolism in Pancreatic Cancer: Breaking Down a Complex Clinical Dilemma.预防胰腺癌患者静脉血栓栓塞症:破解复杂的临床难题。
Oncologist. 2020 Feb;25(2):132-139. doi: 10.1634/theoncologist.2019-0264. Epub 2019 Oct 1.
10
High Risk of Symptomatic Venous Thromboembolism After Surgery for Spine Metastatic Bone Lesions: A Retrospective Study.脊柱转移瘤术后症状性静脉血栓栓塞症的高风险:一项回顾性研究。
Clin Orthop Relat Res. 2019 Jul;477(7):1674-1686. doi: 10.1097/CORR.0000000000000733.

引用本文的文献

1
Extended pharmacological thromboprophylaxis and clinically relevant venous thromboembolism after major abdominal and pelvic surgery: international, prospective, propensity score-weighted cohort study.大型腹部和盆腔手术后延长药物性血栓预防与临床相关静脉血栓栓塞:国际前瞻性倾向评分加权队列研究
Br J Surg. 2025 Mar 4;112(3). doi: 10.1093/bjs/znaf005.
2
Venous Thromboembolism and Primary Thromboprophylaxis in Perioperative Pancreatic Cancer Care.围手术期胰腺癌护理中的静脉血栓栓塞与初级血栓预防
Cancers (Basel). 2023 Jul 8;15(14):3546. doi: 10.3390/cancers15143546.